• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NeueHealth Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/8/25 5:11:35 PM ET
    $NEUE
    Medical Specialities
    Health Care
    Get the next $NEUE alert in real time by email
    bhg-20250507
    0001671284false9250 NW 36th St Suite 420DoralFlorida00016712842025-05-072025-05-07


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    Date of Report (date of earliest event reported) May 7, 2025

    NeueHealth, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    001-40537
    47-4991296
    (State or other jurisdiction of incorporation or organization)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    9250 NW 36th St Suite 420, Doral, Florida
    33178
    Address of Principal Executive Office(Zip Code)
    (612) 238-1321
    Registrant's telephone number, including area code

    Not Applicable
    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.0001 per shareNEUENew York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    o



    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On May 7, 2025, NeueHealth, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) to consider certain proposals related to the Agreement and Plan of Merger, dated as of December 23, 2024 (the “Merger Agreement”), by and among NH Holdings 2025, Inc., a Delaware corporation (“Parent”), and NH Holdings Acquisition 2025, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company. Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. On the terms and subject to the conditions set forth in the Merger Agreement, among other things, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, the Company will no longer be a public company.

    As of the close of business on April 11, 2025, the record date for the Special Meeting, there were 8,927,758 shares of common stock of the Company, par value $0.0001 per share (the “Company Common Stock”), outstanding, 750,000 shares of Series A Convertible Perpetual Preferred Stock of the Company, par value $0.0001 per share (“Company Series A Preferred Stock”), outstanding and 175,000 shares of Series B Convertible Perpetual Preferred Stock of the Company, par value $0.0001 per share (“Company Series B Preferred Stock” and, together with the Company Series A Preferred Stock, the “Company Preferred Stock”), outstanding. Holders of shares of Company Common Stock were entitled to one vote per share on each of the Merger Agreement Proposal (as defined below), the Adjournment Proposal (as defined below) and the Merger-Related Compensation Proposal (as defined below). Holders of shares of Company Series A Preferred Stock (voting on an as-converted basis) were collectively entitled to a total of 3,388,898 votes on each of the Merger Agreement Proposal and the Adjournment Proposal. Holders of shares of Company Series B Preferred Stock (voting on an as-converted basis) were collectively entitled to a total of 2,182,376 votes on each of the Merger Agreement Proposal and the Adjournment Proposal. Holders of shares of Company Common Stock and Company Preferred Stock (voting on an as-converted basis) collectively entitled to a total of 8,597,939 votes, representing approximately 59.3% of the total voting power of the outstanding shares of Company Common Stock and Company Preferred Stock (voting on an as-converted basis) entitled to vote at the Special Meeting, were virtually present or represented by proxy at the Special Meeting, constituting a quorum to conduct business with respect to a vote on the Merger Agreement Proposal and the Adjournment Proposal. Holders of a total of 5,564,234 shares of Company Common Stock, representing approximately 62.3% of the voting power of the outstanding shares of Company Common Stock entitled to vote at the Special Meeting, were virtually present or represented by proxy at the Special Meeting, constituting a quorum to conduct business with respect to a vote on the Merger-Related Compensation Proposal.

    At the Special Meeting, the following proposals were considered:
    1.Merger Agreement Proposal. A proposal to adopt the Merger Agreement, which provides that, among other things and on the terms and subject to the conditions set forth therein, the parties thereto will consummate the Merger, pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Parent, pursuant to and in accordance with the Delaware General Corporation Law (the “Merger Agreement Proposal”).

    2.The Adjournment Proposal. One or more proposals to adjourn the Special Meeting to a later date or dates if necessary or appropriate, including adjournments to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Merger Agreement Proposal (the “Adjournment Proposal”).

    3.The Merger-Related Compensation Proposal. Only in the case of holders of shares of Company Common Stock, a nonbinding, advisory proposal regarding certain compensation arrangements for the Company’s named executive officers in connection with the Merger (the “Merger-Related Compensation Proposal”).

    Each proposal is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 14, 2025, as supplemented, and first mailed to the Company’s stockholders on or about April 14, 2025.

    Each of the three proposals was approved by the requisite vote of the Company’s stockholders.

    The final voting results for each proposal are described below.

    (1) Merger Agreement Proposal.
    For
    Against
    Abstain
    8,417,744179,725470


    (2) Adjournment Proposal.



    For
    Against
    Abstain
    8,471,284115,02011,635


    (3) Merger-Related Compensation Proposal.
    For
    Against
    Abstain
    5,314,345236,92212,967

    Because the Merger Agreement Proposal was approved by the requisite vote, no adjournment to solicit additional proxies was necessary.



    Item 9.01    Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit
    No.
    Description
    104The cover page from the Current Report on Form 8-K formatted in Inline XBRL.



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    NeueHealth, Inc.
    Date:05/08/2025By:/s/ Jeff Craig
    Name:Jeff Craig
    Title:General Counsel and Corporate Secretary


    Get the next $NEUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEUE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeueHealth Reports First Quarter 2025 Results

      Delivered strong first quarter performance as care model continues to resonate with consumers, providers, and payors across the healthcare industry Drove positive Adjusted EBITDA for the fifth consecutive quarter, providing a strong foundation for continued success in 2025 and beyond Served approximately 709,000 consumers, an increase of 51% over the first quarter of 2024 NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its first quarter ended March 31, 2025. "We are starting 2025 in a very strong position, generating substantial growth in the number of consumers we serve and delivering another

      5/8/25 6:45:00 AM ET
      $NEUE
      Medical Specialities
      Health Care
    • NeueHealth to Host First Quarter 2025 Earnings Conference Call on May 8, 2025

      NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report first quarter financial results before the financial markets open on Thursday, May 8, 2025, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests participant

      4/23/25 8:00:00 AM ET
      $NEUE
      Medical Specialities
      Health Care
    • NeueHealth Reports Fourth Quarter and Full Year 2024 Results

      Delivered strongest financial performance to date in 2024, resulting from continued success of value-driven, consumer-centric care model Drove positive Adjusted EBITDA for the fourth consecutive quarter in 2024, establishing the foundation for continued strong performance in 2025 and beyond Generated significant growth to start 2025, serving 717,000 consumers, an increase of 48% compared to 2024 NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2024. "In 2024, we delivered our strongest financial performance to date, demonstrating the power of our

      3/20/25 6:45:00 AM ET
      $NEUE
      Medical Specialities
      Health Care

    $NEUE
    Financials

    Live finance-specific insights

    See more
    • NeueHealth Reports First Quarter 2025 Results

      Delivered strong first quarter performance as care model continues to resonate with consumers, providers, and payors across the healthcare industry Drove positive Adjusted EBITDA for the fifth consecutive quarter, providing a strong foundation for continued success in 2025 and beyond Served approximately 709,000 consumers, an increase of 51% over the first quarter of 2024 NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its first quarter ended March 31, 2025. "We are starting 2025 in a very strong position, generating substantial growth in the number of consumers we serve and delivering another

      5/8/25 6:45:00 AM ET
      $NEUE
      Medical Specialities
      Health Care
    • NeueHealth to Host First Quarter 2025 Earnings Conference Call on May 8, 2025

      NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report first quarter financial results before the financial markets open on Thursday, May 8, 2025, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests participant

      4/23/25 8:00:00 AM ET
      $NEUE
      Medical Specialities
      Health Care
    • NeueHealth Reports Fourth Quarter and Full Year 2024 Results

      Delivered strongest financial performance to date in 2024, resulting from continued success of value-driven, consumer-centric care model Drove positive Adjusted EBITDA for the fourth consecutive quarter in 2024, establishing the foundation for continued strong performance in 2025 and beyond Generated significant growth to start 2025, serving 717,000 consumers, an increase of 48% compared to 2024 NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2024. "In 2024, we delivered our strongest financial performance to date, demonstrating the power of our

      3/20/25 6:45:00 AM ET
      $NEUE
      Medical Specialities
      Health Care

    $NEUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Scherman Jeffrey J sold $9,039 worth of shares (1,373 units at $6.58), decreasing direct ownership by 10% to 12,234 units (SEC Form 4)

      4 - NeueHealth, Inc. (0001671284) (Issuer)

      3/17/25 8:40:45 PM ET
      $NEUE
      Medical Specialities
      Health Care
    • GC & Corporate Secretary Craig Jeffery Michael sold $23,001 worth of shares (3,494 units at $6.58), decreasing direct ownership by 15% to 20,104 units (SEC Form 4)

      4 - NeueHealth, Inc. (0001671284) (Issuer)

      3/17/25 8:39:34 PM ET
      $NEUE
      Medical Specialities
      Health Care
    • EVP, Consumer Care Orozco Tomas sold $31,375 worth of shares (4,766 units at $6.58), decreasing direct ownership by 14% to 29,325 units (SEC Form 4)

      4 - NeueHealth, Inc. (0001671284) (Issuer)

      3/17/25 8:38:23 PM ET
      $NEUE
      Medical Specialities
      Health Care

    $NEUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by NeueHealth Inc. (Amendment)

      SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)

      4/10/24 9:52:09 PM ET
      $NEUE
      Medical Specialities
      Health Care

    $NEUE
    SEC Filings

    See more
    • SEC Form 10-Q filed by NeueHealth Inc.

      10-Q - NeueHealth, Inc. (0001671284) (Filer)

      5/9/25 6:34:33 AM ET
      $NEUE
      Medical Specialities
      Health Care
    • NeueHealth Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NeueHealth, Inc. (0001671284) (Filer)

      5/8/25 5:11:35 PM ET
      $NEUE
      Medical Specialities
      Health Care
    • NeueHealth Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NeueHealth, Inc. (0001671284) (Filer)

      5/8/25 6:46:30 AM ET
      $NEUE
      Medical Specialities
      Health Care